| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100 - 1/500 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 1143 |
| clone | 1H11F2 |
| WB Predicted band size | 56.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHRNB4 (AA: extra 22-236) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CHRNB4抗体的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Selective Localization of the CHRNB4 Subunit in Dopaminergic Neurons Using a Novel Polyclonal Antibody*
**作者**：Smith, J. et al.
**摘要**：开发了一种特异性抗CHRNB4多克隆抗体，通过免疫组化发现其在啮齿类动物中脑多巴胺能神经元中高表达，提示其可能参与尼古丁成瘾的神经环路。
2. **文献名称**：*Validation of a CHRNB4-Specific Antibody for Western Blot and Immunoprecipitation in Murine Models*
**作者**：Brown, T. et al.
**摘要**：验证了一种抗CHRNB4单克隆抗体的特异性，证明其适用于Western blot和免疫沉淀，成功检测到小鼠脑组织中CHRNB4的蛋白表达变化。
3. **文献名称**：*CHRNB4 Antibody Reveals Altered Expression in Nicotine-Induced Neuroplasticity*
**作者**：Lee, H. et al.
**摘要**：利用CHRNB4抗体研究尼古丁暴露后小鼠前额叶皮层和伏隔核的受体表达变化，发现其与突触可塑性相关的上调现象。
4. **文献名称**：*Development of a High-Affinity Monoclonal Antibody Targeting the CHRNB4 Subunit for Neuropathology Studies*
**作者**：Garcia, R. et al.
**摘要**：报道了一种高亲和力单克隆抗体的开发，通过免疫荧光和流式细胞术验证其在阿尔茨海默病模型中检测CHRNB4异常聚集的应用。
---
**备注**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台以关键词“CHRNB4 antibody”、“nAChR β4 subunit”等检索。建议结合具体研究场景(如疾病模型、实验技术)进一步筛选文献。
The CHRNB4 antibody targets the beta-4 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels critical for synaptic signaling in the nervous system. Encoded by the *CHRNB4* gene, the β4 subunit combines with α subunits (e.g., α3. α4) to form functional receptor complexes. These receptors modulate neurotransmitter release, particularly dopamine and glutamate, influencing processes like cognition, reward, and addiction.
CHRNB4-containing receptors are predominantly expressed in the habenulo-interpeduncular pathway, autonomic ganglia, and select brain regions, linking them to behaviors such as nicotine dependence, anxiety, and pain modulation. Antibodies against CHRNB4 are essential tools for studying receptor localization, expression levels, and subunit composition in tissues or cell models. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding research on receptor trafficking, synaptic plasticity, and disease mechanisms.
Dysregulation of CHRNB4 has been implicated in neurological disorders, including epilepsy, schizophrenia, and nicotine addiction. For example, genetic variations in *CHRNB4* are associated with altered nicotine sensitivity and smoking behaviors. CHRNB4 antibodies also support drug discovery by validating target engagement in preclinical studies. Their specificity ensures accurate detection, though validation across species and applications is critical due to sequence homology among nAChR subunits. Overall, these antibodies advance understanding of cholinergic signaling and its therapeutic potential.
×
